Deep Dive: Biocon’s Global Gamble — Growth, Debt, and the Biosimilar Bet

Biocon has transformed itself from a small Bengaluru biotech startup into India’s largest global biopharmaceutical powerhouse, supplying complex medicines to more than 120 countries. But this explosive growth came at a price. After a massive 3.3 billion dollar acquisition of the Viatris biosimilars business, revenue has surged while profits have sharply declined under the weight of debt, integration costs, and regulatory pressure.In this episode of The India Financial Pulse, we take a full-scale deep dive into Biocon Limited — its origins, business model, biosimilars strategy, financial performance, valuation, competitive moat, and the major risks investors must watch closely. We explore whether Biocon’s ambitious global expansion will ultimately create a pharmaceutical giant for the future or become a cautionary tale of overexpansion and financial strain.From FDA observations and debt burdens to obesity drug opportunities and fair value estimates, this episode breaks down the complete investment story behind one of India’s most important biotech companies.